🇺🇸

US SEC Filing Intelligence

· daily

High-Value Federal Grants ($5M+) — May 06, 2026

These four high-value civilian federal grants, totaling $737,191,282 in obligations with zero defense-related awards, highlight steady execution in infrastructure and services sectors led by the Department of Veterans Affairs (VA) at ~$329M across two contracts and General Services Administration (GSA) infrastructure via Hensel Phelps. The highest-conviction signal is bullish on Hensel Phelps Construction Co.'s $188,297,215 GSA contract, with 76% ($143M) already outlayed on a cost-plus incentive fee structure for Calexico West Land Port modernization, signaling reliable revenue through 2026. Neutral signals dominate Peraton Inc. ($220M NASA balloon facility ops), Vendor Resource Management ($200M VA real estate), and Favor Techconsulting ($128M VA IT), where low outlays (e.g., 19% on Vendor, 13% on Favor) temper near-term revenue recognition. A key risk is execution delays on under-outlayed VA contracts amid fixed-price structures, warranting watches on option exercises and 2025-2026 end dates.

4 total filings
· daily

General Federal Contracts — May 06, 2026

These four civilian contracts total $737,191,282 in obligations with zero defense exposure, highlighting steady federal spending in NASA R&D operations, VA real estate/IT services, and GSA construction. Dominant themes include VA awards totaling $328,828,351 across Vendor Resource Management ($200M) and Favor TechConsulting ($128M), alongside major infrastructure at GSA ($188M to Hensel Phelps). The highest-conviction signal is bullish for Hensel Phelps Construction Co., with $143M (76%) already outlayed on its $188M GSA contract nearing completion in 2026. Key risk is execution delays from low outlays in VA contracts (Vendor Resource at 19%, Favor TechConsulting at 13%), warranting monitoring of option exercises and performance milestones.

4 total filings
· daily

All NASA Contracts — May 06, 2026

NASA accounts for the full $220,065,714 obligation across this single civilian contract stream (0 defense-related), centered on Peraton Inc.'s long-term operations and management of the NASA Balloon Facility. Awarded via full and open competition in 2014, the cost-plus-fixed-fee contract provides Peraton with an estimated $21.5M in steady annual revenue through April 2025, with $89.9M (41%) already outlayed and $71.6M via 261 subawards. The highest-conviction neutral signal (5/10 strength, 6/10 materiality) reflects low pricing risk but partial execution and subcontractor reliance. A key watch item is progress on the remaining $130M obligation ahead of the 2025-04-30 end date and potential follow-on awards.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 06, 2026

Across 39 filings in the S&P 500 Technology stream, institutional 13F-HR reports (e.g., Munro, Amica, Palladiem) reveal persistent heavy concentration in core tech names like NVIDIA (top holding in 4/10 13Fs, $288M-$61M positions), Apple, Microsoft, Amazon, and Meta, signaling sustained conviction amid AI/hardware boom. Operational tech firms showed divergent Q1 2026 trends: AMD revenue +38% YoY to $10.3B, EPS +91% to $0.84; Arista +35% to $2.7B, op income +35% to $1.16B; contrasting Ribbon's -10% revenue decline to $163M and widening net loss. Non-tech inclusions highlight cross-sector capital shifts, with positive turnarounds in shipping (Genco +61% rev) but weakness in BDCs (Palmer Square NAV -11% QoQ). Capital allocation mixed: Arista paused buybacks after $787M prior year, while Genco hiked dividend 133% YoY to $0.35/share; forward guidance stable/reaffirmed in Acadia/Immunocore. Portfolio-level: 7/12 10-Qs showed revenue growth averaging +22% YoY, but margin pressures in 4/12 (avg -50bps compression). Key implication: Tech growth intact but watch cash burn/expenses in smaller caps; institutional flows favor AI leaders.

16 high priority 23 medium 39 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 06, 2026

Across 35 filings from NASDAQ-100 related entities, Q1 2026 earnings reveal robust revenue growth in 8/12 operating companies (avg +18% YoY, led by AMD +38% and Kennametal +22%), but mixed profitability with 6/12 showing margin compression or expense pressures (avg op margin flat to -100bps). Institutional 13F-HR filings (13/35) highlight concentrated tech exposure, with NVIDIA topping 5 funds (e.g., Munro $288M, AMICA $61M), signaling sustained conviction in AI/semiconductors. Shipping (Genco) posted a sharp turnaround (+60% revenues, dividend +133% YoY), while biotechs (Immunocore +14% sales, Lyell loss -54%) and autos (Adient +7% sales, profit swing) show recovery glimmers amid cash burn concerns. Capital allocation leans shareholder-friendly with dividends declared in 5 firms (e.g., Genco $0.35, Kennametal $0.20) and buybacks (United Community $37M, Mueller $5.5M). Forward guidance mostly raised/affirmed (Kennametal EPS +18%, Murphy prod beat), building a catalyst-rich H2 2026 calendar. Portfolio implication: Overweight growth industrials/tech, monitor inventory drags and biotech trials for alpha.

14 high priority 21 medium 35 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 06, 2026

Across 50 SEC filings from S&P 500 Financials and related streams dated May 6, 2026, key themes include mixed Q1 2026 earnings with 14/22 reporting companies showing YoY revenue growth averaging +15% (e.g., Clear Secure +19.7%, Amcor +77%), but margin compression in 10/22 averaging -180 bps amid higher costs and investments; robust capital allocation via dividends/buybacks in 9 filings (e.g., Acushnet $10M repurchase, Clear $56.4M returns); and active M&A/debt markets with SPAC IPOs (Quantum Leap $200M, Plutonian $100M) and financings (Bread Financial 4.8M pref shares, Blackstone $450M notes). Financials-specific trends highlight mortgage/REIT consolidation (Two Harbors $11.30/share acquisition at 14% premium) and bank procedural updates (Woori dissent notices, Patriot Q1 prelims). Forward-looking signals positive with 8/15 guidance raises (e.g., BeOne revenue to $6.3-6.5B, LivaNova EPS to $4.20-4.30), building a Q2-Q3 catalyst calendar; 13F-HR filings (14 total) reveal concentrated tech/AI bets (NVIDIA top in 5/14). Portfolio implications: overweight resilient growth names with raised guidance, monitor margin pressures and SPAC de-SPAC risks for alpha.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 06, 2026

Across 50 pre-analyzed SEC filings in the USA S&P 500 Consumer Staples intelligence stream (despite diverse sector representation), Q1 2026 results reveal resilient revenue growth in 70% of reporting companies (avg +9% YoY, ranging from PureCycle +161% to QuidelOrtho -10.5%), tempered by mixed margins (expansions in Elanco +21% Adj EBITDA, Clear Secure +720 bps; compressions in Edgewell -410 bps, Kraft Heinz adj op inc -11.8%). Capital allocation trends emphasize shareholder returns with 15+ companies declaring dividends (e.g., Deluxe $0.30/share, Clear Secure $0.15/share + $56M repurchases) and buybacks (TKO +$1B authorization), alongside debt reductions (Deluxe -$32M, Littelfuse -$166M). Forward-looking statements show 60% guidance raises/reaffirms (Elanco revenue $5.01-5.085B +5-7% org CC, Clear Secure FCF +35.5%), building a catalyst calendar amid M&A momentum (Apellis $41/share + CVR tender, Clear Channel $2.43/share merger by Q3'26). Sentiment skews mixed (55%), with positive outliers in consumer-facing growth (Clover Health rev +62%, members +51%) but bearish pressures from impairments/litigation (Atkore $137M settlement, Fresh Del Monte $20M). Portfolio-level patterns indicate sector stability via promotions (GIS COO elevation) and operational turnarounds (JBT Marel net income +$218M YoY), signaling actionable opportunities in undervalued staples amid modest organic growth (Kraft Heinz -0.4%, Edgewell -2.4%). Overall implications favor defensive positioning with selective growth bets on guidance outperformers.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 06, 2026

Across 50 filings in the USA S&P 500 Industrials stream (broadly including adjacent sectors like energy, pharma, and machinery), sentiment is predominantly mixed (24/50), with 10 positive and 12 neutral/low materiality 13F snapshots; YoY revenue growth averages +20% in 18 key reporters (e.g., AMD +38%, Pattern +43%, ITT +33%), but QoQ declines prevalent in cash/assets (e.g., 8/15 showed -10%+ cash drops) and margins compressed in 7/12 (avg -150bps). Net income surged in outperformers like Parke Bancorp (+52% YoY), SandRidge (+44%), GEO (+96%), but biotechs/pharma (12 filings) reported widened losses from R&D spikes (e.g., Mirum +$775M net loss). Capital allocation bullish: 10 companies hiked dividends/buybacks (e.g., SandRidge +8%, ITT $0.386/share), 5 M&A/deals (e.g., Fresh Del Monte $308M acquisition). Guidance raised in 9/15 (e.g., Pattern +32%, LandBridge $210-230M EBITDA), signaling momentum; portfolio trend: Industrials/energy outperform biotechs on profitability. Implications: Tactical buys in growth industrials (ITT, JCI), caution on cash-burn biotechs; alpha from catalysts like Phase 3 readouts H2 2026.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 06, 2026

Across 17 filings in the USA S&P 500 Energy intelligence stream (with energy-relevant subset including Devon, APA, Chesapeake Utilities, Dorchester Minerals, Hallador Energy, ONEOK), Q1 2026 results show mixed performance: producers like Devon (-14% YoY revenue, -76% net earnings) and Hallador (-13.5% revenue, net loss vs profit) faced headwinds from lower oil/gas/NGL sales and electric volumes, while royalties (Dorchester +36% revenue, +65% net income) and utilities (Chesapeake +18.3% revenue, +16.5% net income) outperformed on volume growth and regulatory tailwinds. APA raised full-year US oil production guidance to 122k bbl/d amid cost savings progress toward $450M, and Hallador secured a 12-year $1B+ capacity deal doubling forward book. Capital allocation trends favor shareholder returns (Dorchester distribution +2% YoY per unit, Chesapeake dividends +7% YoY) and deleveraging (Hallador bank debt to $0, APA repaid $634M bonds). Institutional 13Fs (HughesLittle, Westchester, Copeland) provide neutral snapshots with no major energy shifts. Non-energy filings (Papa Johns mixed AGM votes, Williams Sonoma strong proxy TSR) signal broader market governance focus. Portfolio implication: rotate to resilient midstream/royalties amid E&P volatility, watch Q2 catalysts for guidance updates.

7 high priority 10 medium 17 total filings
· daily

US Material Events SEC 8-K Filings — May 06, 2026

Across 50 US SEC filings from May 6, 2026, dominant themes include widespread executive transitions (14+ cases of promotions, departures, or appointments, e.g., General Mills COO promotion, Anavex interim CEO), mixed Q1 2026 earnings with average revenue growth of ~10% YoY in reporting firms but frequent margin compressions (e.g., -2750 bps at Energy Recovery, -300 bps at Instacart), and robust capital markets activity via debt issuances/refinancings (e.g., Core Scientific $3.3B notes, Amphenol €1.1B), buybacks (Instacart $349M, Energy Recovery $25M auth), and M&A/divestitures (Broadwind Abilene sale for $19.5M). Portfolio-level trends show 7/12 earnings reporters with YoY revenue growth (avg +12%), but 6/12 with EBITDA/operating losses widening or margins contracting avg -800 bps, signaling cost pressures amid growth. Positive AGMs (90%+ approval rates in Leidos, Mativ) reflect shareholder alignment, while guidance changes are split: 3 raises (908 Devices FY rev to $67-70M), 1 withdrawal (Broadwind). Sector patterns favor energy/financials with liquidity boosts, but tech/biotech shows leadership churn risks. Implications: Near-term catalysts from earnings calls; favor firms with buybacks/guidance beats for alpha, monitor margin trends for industrials.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 06, 2026

The 50 pre-analyzed SEC filings for USA Dow Jones 30 stream reveal a resilient Q1 2026 earnings season with 18/25 quarterly reporters showing YoY revenue growth averaging +28% (range 4%-108%, led by Viper Energy +108% and Lumentum +90%), though profitability is mixed with 12/25 net income declines averaging -25% due to margin compression (-150bps avg in 8 cases) from rising costs, special charges, and op expenses. Capital allocation remains shareholder-friendly, with 14 companies announcing/declaring dividends (e.g., Acushnet $0.255/share, Flowco +12.5% to $0.09) and 10 executing buybacks totaling ~$300M (e.g., Ingevity $52M, Life Time $62.7M). M&A activity heats up with positive updates on Skyworks-Qorvo (Phase II China review, $500M synergies), Two Harbors-CCM ($11.30/share, Q3 close), and Clear Channel take-private ($2.43/share, vote May 12). Guidance raised in 5 cases (CVS Adjusted EPS $7.30-7.50, LivaNova $4.20-4.30), reaffirmed in 6, signaling cautious optimism; 13F filings show institutional tilt to tech megacaps (NVIDIA, Apple, Amazon topping 8/10 portfolios). Sector patterns highlight energy/materials outperformance vs. manufacturing/construction weakness, with portfolio-level trend of deposit/asset contractions in banks (Parke -2% assets QoQ) but robust cash flows in tech/healthcare. Key implications: Favor growth names with raised guidance and buybacks for near-term upside, monitor M&A catalysts and margin trends for volatility.

20 high priority 30 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — May 06, 2026

Across 50 SEC filings for May 6, 2026, Q1 2026 earnings dominate with mixed results: 8/15 reporting companies showed revenue growth averaging +12% YoY (e.g., Clear Secure +19.7%, BeOne +35%), but 5/15 faced declines averaging -15% YoY (e.g., Owens Corning -10%, LP -21%), highlighting cyclical weakness in building materials vs resilience in tech/healthcare. Guidance was raised by 6 companies (e.g., Taboola revenue to $2.0-2.1B, LivaNova EPS +$0.05 midpoint), signaling confidence amid margin pressures (avg compression -100bps in mixed sentiment firms). Capital returns accelerated with dividends declared by 7 firms (e.g., Acushnet $0.255/sh, Deluxe $0.30/sh) and buybacks (Clear Secure $56M, Acushnet $10M Q1). M&A/SPAC activity surged with TWO Harbors pushing CCM deal at 14% premium (close Q3 2026), Qorvo/Skyworks merger advancing (late 2026), and 4 SPAC IPOs priced (e.g., Quantum Leap $200M). 13F filings (14 total) reveal heavy tech concentration (NVDA top in 6/14, avg 20% portfolio weight), underscoring AI enthusiasm. Building products face headwinds (OSB prices -31% YoY at LP), while healthcare/biotech shows royalty-driven gains (BeOne Amgen +231% YoY). Overall, actionable tilt to growth names with catalysts, monitor cyclicals for Q2 guidance.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 06, 2026

Across 50 SEC filings from the S&P 500 Consumer Discretionary stream (primarily retail, automotive, restaurants, hotels, entertainment), sentiment is predominantly mixed with 14/25 detailed financial reporters showing YoY revenue growth averaging +12% (e.g., YUM Brands +15%, Marriott RevPAR +4.2%), but margins compressed in 7/15 cases by avg -150 bps amid higher expenses and impairments. Capital allocation remains shareholder-friendly with $1.5B+ in buybacks/dividends (Marriott $0.7B repurchases, SandRidge dividend +8%, Life Time $62M buyback), while M&A activity accelerates (Fresh Del Monte $307M acquisition, Nuveen $347M asset purchase). Forward guidance mixed: 5 raises (Freshpet to 8-11% sales growth) vs 4 cuts (Louisiana-Pacific Siding -2% FY2026). 13F filings reveal institutional conviction in tech-discretionary overlap (Apple/NVIDIA top holdings in multiple). Key theme: Resilience in hospitality/foodservice vs cyclical pressures in building/produce; portfolio implication: overweight restaurants/hotels, underweight commodities-exposed names.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 06, 2026

Across 50 SEC filings from the USA S&P 500 Healthcare stream (primarily pharmaceuticals, biotech, med devices, providers, with some cross-sector), Q1 2026 results reveal mixed performance: 12/18 reporting companies showed YoY revenue growth averaging +18% (led by BeOne Medicines +35%, CoreCivic +25.8%, CVS +6.2%), but 6 experienced declines averaging -15% (e.g., Castle Biosciences -5%, Louisiana-Pacific -21%). Margin trends are divergent with improvements in 7 firms (e.g., Castle gross margin +24pts to 73%, BeOne +4pts to 89%) offset by compressions in 5 (e.g., Edgewell -410bps, Green Thumb -340bps). Guidance was raised by 9 companies (e.g., BeOne FY rev to $6.3-6.5B, CVS Adj EPS $7.30-7.50), signaling optimism amid capex surges and buybacks ($200M+ returned across firms like News Corp $1B program, Chime $200M auth). Capital allocation favors returns (dividends doubled at Atmos, NVE $1.00/shr) over reinvestment, with M&A active (Corebridge-Equitable synergies, CoreCivic $148M acquisition). Biotech catalysts dominate (Revolution Medicines Ph3 success, Sight Sciences $55M patent win), but leadership changes (Anavex CEO exit) and expense inflation pose risks. Portfolio implication: overweight high-growth biopharma with raised guidance, monitor med device margin pressures.

17 high priority 33 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 06, 2026

Across 11 DEF 14A proxy statements, overarching themes include routine director elections (10/11 filings), advisory say-on-pay votes on 2025/2026 executive compensation (7/11), auditor ratifications (8/11), and governance enhancements like officer exculpation amendments and equity plan expansions, with all AGMs clustered in June 2026. Period-over-period trends are sparse but highlight exceptional performance at Williams Sonoma (FY2025 record $8.84 EPS, 18.1% op margin, 3.5% comp brand revenue growth, 241% 3yr TSR vs peer 22%) and BJ's Wholesale (100% director attendance, zero insider policy violations), contrasting Lithium Americas' mixed lithium price declines to June 2025 lows followed by H2 recovery amid Thacker Pass funding ($905.6M cash, 93% engineering complete). No widespread margin compression or revenue declines noted; instead, positive governance and project milestones dominate. Portfolio-level patterns show strong consumer/retail conviction (2/11 with positive sentiment), routine fund/BDC filings (4/11 neutral), and dilution risks from equity plans (e.g., Fluent +52% shares). Market implications: High approval odds for proposals boost stability, but watch comp votes and virtual AGMs for shareholder sentiment signals ahead of summer catalysts.

11 high priority 11 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 06, 2026

The IPO Pipeline stream reveals four S-1 filings dominated by SPAC IPOs, share resales, and post-merger registrations, signaling renewed activity in blank-check companies and secondary offerings amid mixed/neutral sentiments. Futurewave Acquisition Corp launches a $50M SPAC IPO with Nasdaq listing imminent, while Caring Brands and Merlin face dilution from 18.9M and 13.3M share resales respectively, potentially inflating share counts by 3x and fulfilling PIPE rights. SHF Holdings highlights ongoing merger extensions to October 2025 and Series B financing, but no explicit period-over-period financial trends emerge across filings due to pre-revenue SPAC/resale focus. Critical risks include up to $7.73/share dilution at Futurewave and Caring Brands' Nasdaq equity deficiency ($2.09M vs minimum), with compliance due May 22, 2026. Portfolio-level patterns show 3/4 filings involving resale/dilution (avg potential share increase 200%+), contrasting pure SPAC IPO; implications favor short-term trading around listings/compliance but caution on post-IPO redemptions and delisting.

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — May 06, 2026

Across 50 filings on May 6, 2026, Q1 2026 results reveal mixed performance with 12/23 10-Q filers showing YoY revenue growth averaging +25% (e.g., AMD +38%, Arista +35%, Lumentum +90%), driven by tech and select financials/energy, but offset by margin compression in 8/23 (-avg 150bps, e.g., Solstice -277bps, Owens Corning gross margin -30%) and losses in materials/healthcare (e.g., HNI swung to -$38.8M, Ultragenyx net loss -23% worse). SPAC/IPO activity surges with 5 new offerings (e.g., Plutonian $100M IPO, Quantum Leap $200M), signaling capital influx into blank checks targeting AI/quantum. M&A catalysts advance positively (Skyworks-Qorvo Phase II China review, late 2026 close; Corebridge-Equitable synergies $500M+), while insolvencies (Tayo Rolls CIRP deadlock) and regulatory actions (Velan Hotels defaults) flag distress. Capital returns robust in 7 firms (e.g., Solstice $0.075 div, YUM $185M buybacks, Bristow $11M treasury), but cash burns rise in biotech (Ultragenyx -$197M ops cash). Portfolio trend: Outperformers in tech/fintech (avg equity +20% QoQ) vs underperformers in energy/materials (avg assets -5% QoQ), with forward guidance stable/reaffirmed in key names positioning for H2 catalysts.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 06, 2026

Across 50 Q1 2026 filings, mixed sentiments dominate (44/50 mixed or negative), with revenue growth averaging +15% YoY in outperformers like tech (AMD +38%, Arista +35%, Lumentum +90%) but declines in energy (Talos -8%), diagnostics (QuidelOrtho -10.5%), and utilities (Tucson Electric -7.5%); margins compressed in 28/50 companies (avg -150 bps where noted, e.g., Atkore -27% gross profit drop). Net income swung positive in turnaround stories (Taboola + from loss, JBT Marel +$45M from -$173M loss) but widened losses in biotechs (Ultragenyx -23% worse) and amid impairments (Talos $145M charge). Capital returns strong with buybacks (United Therapeutics $1.5B, Arista prior $787M but paused) and dividends (Yum +$0.04/share YoY), though cash piles shrank QoQ in 32/50 (avg -15%). Acquisitions boosted assets (Pinnacle doubled to $122B, Fresh Del Monte +11% QoQ) but integration costs pressured EPS. Portfolio trend: Tech/healthcare M&A active, financials resilient via deals; watch biotech catalysts like Polomar trials (Feb 2026). Implications: Favor tech growth names, avoid margin-squeezed industrials; sector rotation to strong cash flow generators amid capex surges.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — May 06, 2026

Across the single filing in the USA Trading Suspensions stream, Sadot Group Inc. (SDOT) dominates with a critical Form 8-K disclosing a notice of delisting or failure to satisfy continued listing standards under Item 3.01, signaling acute regulatory compliance risks in the restaurant sector (SIC 5810). No period-over-period financial trends, insider activity, forward-looking guidance, capital allocation details, or positive offsets were noted in the enriched data, amplifying the negative sentiment rated 10/10 materiality. This isolated but high-impact event underscores portfolio-level vulnerability to delistings amid US exchange halts, with potential for trading suspension and share value erosion. Item 5.03 hints at governance changes like amendments to articles of incorporation or bylaws, but lacks timelines or bullish catalysts. Investors face immediate bearish implications, including OTC trading risks post-delisting and eroded liquidity. No cross-company trends emerge from the 1-filing sample, but restaurant operators appear prone to listing failures without offsetting metrics like revenue growth or insider buying.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 06, 2026

Across 43 filings in the USA Corporate Distress & Bankruptcy stream, financing activities dominate with 25+ companies announcing debt issuances, credit amendments, or equity offerings to enhance liquidity, refinance maturities, or fund growth, signaling proactive balance sheet management amid neutral-to-positive sentiments rather than outright distress. Period-over-period trends show mixed earnings: 6/10 reporting companies posted revenue growth (avg +12% YoY, e.g., Solstice +10%, Texas Pacific +21%), but margins compressed in 4/6 (avg -150 bps, e.g., Solstice -277 bps EBITDA margin), with EBITDA flat/declining in several despite sales beats. Capital allocation leans toward shareholder returns (dividends declared by Solstice, Texas Pacific, Carriage) and buybacks/repurchases (Maplebear $349M, Alkami $100M authorized), while forward guidances are mostly reaffirmed or provided positively (Solstice FY26 sales $3.9-4.1B, Maplebear Q2 GTV +11-13%). True distress signals are sparse (1 delisting notice, 1 payables advance, 1 goodwill impairment), but outliers like Sadot's Nasdaq issues and MSP Recovery's restructuring aid highlight pockets of vulnerability. Sector patterns emerge in energy/real estate (facility expansions, e.g., Permian $3B credit) and tech/pharma (financings for commercialization). Implications: Low systemic distress but watch liquidity-dependent firms; opportunities in refinancings enabling M&A/growth.

43 high priority 43 total filings